Compendium of Cancer Genome Aberrations

GTS5:Volunteer Assignments and Opportunities: Difference between revisions

[checked revision][checked revision]
← Older editNewer edit →
VisualWikitext
No edit summary
No edit summary
Line 309: Line 309:
!'''Date of Last Editor Review'''
!'''Date of Last Editor Review'''
!'''Notes'''
!'''Notes'''
|-
|CHAPTER 2 (GROWTH FACTOR RECEPTORS AND RELATED SIGNALLING PATHWAYS)
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|-
|-
|[[GTS5:Hereditary_papillary_renal_carcinoma_(MET)|Hereditary papillary renal carcinoma (MET)]]
|[[GTS5:Hereditary_papillary_renal_carcinoma_(MET)|Hereditary papillary renal carcinoma (MET)]]
Line 727: Line 747:
|
|
|
|
|-
|CHAPTER 3 (OXIDATIVE STRESS RESPONSE AND METABOLISM)
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|-
|-
|[[GTS5:Von_Hippel-Lindau_syndrome_(VHL)|Von Hippel-Lindau syndrome (VHL)]]
|[[GTS5:Von_Hippel-Lindau_syndrome_(VHL)|Von Hippel-Lindau syndrome (VHL)]]
Line 771: Line 811:
|
|
|
|
|-
|CHAPTER 4 (CELL CYCLE AND APOPTOSIS PATHWAYS)
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|-
|-
|[[GTS5:Li-Fraumeni_syndrome_(TP53)|Li-Fraumeni syndrome (TP53)]]
|[[GTS5:Li-Fraumeni_syndrome_(TP53)|Li-Fraumeni syndrome (TP53)]]
Line 837: Line 897:
|
|
|
|
|-
|CHAPTER 5 (DNA REPAIR AND GENOMIC STABILITY)
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|-
|-
|[[GTS5:Lynch_Syndrome_(MLH1,_PMS2,_MSH2,_MSH6)|Lynch Syndrome (MLH1, PMS2, MSH2, MSH6)]]
|[[GTS5:Lynch_Syndrome_(MLH1,_PMS2,_MSH2,_MSH6)|Lynch Syndrome (MLH1, PMS2, MSH2, MSH6)]]
Line 1,090: Line 1,170:
|
|
|
|
|-
|CHAPTER 6 (TELOMERE MAINTENANCE)
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|-
|-
|[[GTS5:Dyskeratosis_congenita_(DKC1,_TERT,_TERC,_TINF2,_Other_IBMFS_genes)|Dyskeratosis congenita (DKC1, TERT, TERC, TINF2, Other IBMFS genes)]]
|[[GTS5:Dyskeratosis_congenita_(DKC1,_TERT,_TERC,_TINF2,_Other_IBMFS_genes)|Dyskeratosis congenita (DKC1, TERT, TERC, TINF2, Other IBMFS genes)]]
Line 1,112: Line 1,212:
|
|
|
|
|-
|CHAPTER 7 (EPIGENETIC DRIVERS AND CHROMATIN REMODELLING)
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|-
|-
|[[GTS5:Beckwith-Wiedemann_spectrum_(IGF2;_CDKN1C)|Beckwith-Wiedemann spectrum (IGF2; CDKN1C)]]
|[[GTS5:Beckwith-Wiedemann_spectrum_(IGF2;_CDKN1C)|Beckwith-Wiedemann spectrum (IGF2; CDKN1C)]]
Line 1,178: Line 1,298:
|
|
|
|
|-
|CHAPTER 8 (RNA REGULATION)
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|-
|-
|[[GTS5:DICER1-related_tumour_predisposition_syndrome_(DICER1)|DICER1-related tumour predisposition syndrome (DICER1)]]
|[[GTS5:DICER1-related_tumour_predisposition_syndrome_(DICER1)|DICER1-related tumour predisposition syndrome (DICER1)]]
Line 1,211: Line 1,351:
|
|
|
|
|-
|CHAPTER 9 (PROTEIN REGULATION)
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|-
|-
|[[GTS5:BAP1-related_tumour_predisposition_syndrome_(BAP1)|BAP1-related tumour predisposition syndrome (BAP1)]]
|[[GTS5:BAP1-related_tumour_predisposition_syndrome_(BAP1)|BAP1-related tumour predisposition syndrome (BAP1)]]
Retrieved from "https://test.ccga.io/index.php/GTS5:Volunteer_Assignments_and_Opportunities"